Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEMETHER study of trastuzumab deruxtecan induction followed by trastuzumab + pertuzumab maintenance in HER2-positive metastatic breast cancer
2023-507306-13-00Phase 2Authorised
- Sponsor
- MEDSIR
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan and trastuzumab in breast cancer, sponsored by MEDSIR. Primary endpoints: 1-year progression-free survival rate and 3-year overall survival rate. Planned start Apr 2025; status: authorised.
02
Drugs
trastuzumab deruxtecantrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-507306-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507306-13-00.